Keywords
clinical outcome
acute exacerbation
COPD
Abstract
Introduction
We examined the association of blood eosinophil counts at the time of AECOPD hospitalization with the risk of ICU admission as well as the hospital lengths of stay and mortality.
Methods
In the current retrospective study, the association between blood eosinophil counts in COPD patients at the time of AECOPD hospitalization and the risk of subsequent ICU admission as well as mortality was assessed. The chi-squared test and t-test were used to compare categorical and continuous variables. The statistical significance level was set at 0.05. Kaplan–Meier curves for mortality as well as ICU admission up to 40 days after discharge from the index hospitalization were constructed using the determined optimal eosinophil threshold derived above and for the predetermined ≥300 vs <300 cells/μL threshold. All analyses were performed using SPSS version 19.
Results
Antibiotic prescription was significantly associated with increased ICU admission (OR=1.57; confidence interval [95%CI] =1.02–2.42. Patients with higher FEV1 had decreased ICU admission (OR=0.98, 95% CI=0.97–1.01, p=0.1) as well as all-cause mortality compared (OR=0.98, 95% CI=0.92–1.04, p=0.58). There were significantly greater mortality rates for patients with higher ESR (OR=1.02, CI=1.01–1.03, p=0.01) and CRP (OR=1.02, 95% CI=1.01–1.03, p=0.01). There were significantly lower ICU admission rates for patients with higher FVC (OR=0.97, 95% CI=0.95–0.98, p=0.002).
Conclusion
Blood eosinophil count could help determine the risk of ICU admission as well as mortality in COPD patients at the time of hospitalization.
References
Segal LN, Martinez FJ. Chronic obstructive pulmonary disease subpopulations and phenotyping. Journal of Allergy and Clinical Immunology. 2018;141(6):1961-71.
Pu J, Yi Q, Luo Y, Wei H, Ge H, Liu H, et al. Blood eosinophils and clinical outcomes in inpatients with acute exacerbation of chronic obstructive pulmonary disease: a prospective cohort study. International Journal of Chronic Obstructive Pulmonary Disease. 2023:169-79.
Agusti A, Vogelmeier C, de Oca M. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2021 report. 2021. 2021.
Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. American journal of respiratory and critical care medicine. 2011;184(6):662-71.
Tashkin DP, Wechsler ME. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. International journal of chronic obstructive pulmonary disease. 2018:335-49.
Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen General Population Study. American journal of respiratory and critical care medicine. 2016;193(9):965-74.
Watz H, Tetzlaff K, Wouters EF, Kirsten A, Magnussen H, Rodriguez-Roisin R, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. The lancet Respiratory medicine. 2016;4(5):390-8.
Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. American journal of respiratory and critical care medicine. 2010;182(5):598-604.
Siddiqui SH, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine. 2015;192(4):523-5.
Couillard S, Larivée P, Courteau J, Vanasse A. Eosinophils in COPD exacerbations are associated with increased readmissions. Chest. 2017;151(2):366-73.
Duman D, Aksoy E, Agca MC, Kocak ND, Ozmen I, Akturk UA, et al. The utility of inflammatory markers to predict readmissions and mortality in COPD cases with or without eosinophilia. International journal of chronic obstructive pulmonary disease. 2015:2469-78.
Chen P-K, Hsiao Y-H, Pan S-W, Su K-C, Perng D-W, Ko H-K. Independent factors associate with hospital mortality in patients with acute exacerbation of chronic obstructive pulmonary disease requiring intensive care unit admission: focusing on the eosinophil-to-neutrophil ratio. PLoS One. 2019;14(7):e0218932.
Greulich T, Tüffers J, Mager S, Eder A, Maxheim M, Alter P, et al. High eosinophil blood counts are associated with a shorter length of hospital stay in exacerbated COPD patients–a retrospective analysis. Respiratory Research. 2020;21:1-8.
Oshagbemi OA, Burden AM, Braeken DC, Henskens Y, Wouters EF, Driessen JH, et al. Stability of blood eosinophils in patients with chronic obstructive pulmonary disease and in control subjects, and the impact of sex, age, smoking, and baseline counts. American journal of respiratory and critical care medicine. 2017;195(10):1402-4.
Rutgers S, Timens W, Kaufmann H, van der Mark TW, Koeter G, Postma D. Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. European Respiratory Journal. 2000;15(1):109-15.
Saltürk C, Karakurt Z, Adiguzel N, Kargin F, Sari R, Celik ME, et al. Does eosinophilic COPD exacerbation have a better patient outcome than non-eosinophilic in the intensive care unit? International journal of chronic obstructive pulmonary disease. 2015:1837-46.
Bafadhel M, Pavord ID, Russell RE. Eosinophils in COPD: just another biomarker? The Lancet Respiratory Medicine. 2017;5(9):747-59.
Brusselle G, Pavord ID, Landis S, Pascoe S, Lettis S, Morjaria N, et al. Blood eosinophil levels as a biomarker in COPD. Respiratory medicine. 2018;138:21-31.
Hegewald MJ, Horne BD, Trudo F, Kreindler JL, Chung Y, Rea S, et al. Blood eosinophil count and hospital readmission in patients with acute exacerbation of chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease. 2020:2629-41.
Yun JH, Lamb A, Chase R, Singh D, Parker MM, Saferali A, et al. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. Journal of allergy and clinical immunology. 2018;141(6):2037-47. e10.
Bélanger M, Couillard S, Courteau J, Larivée P, Poder TG, Carrier N, et al. Eosinophil counts in first COPD hospitalizations: a comparison of health service utilization. International Journal of Chronic Obstructive Pulmonary Disease. 2018:3045-54.
Klion AD. Eosinophilia: a pragmatic approach to diagnosis and treatment. Hematology 2014, the American Society of Hematology Education Program Book. 2015;2015(1):92-7.
Mao Y, Qian Y, Sun X, Li N, Huang H. Eosinopenia predicting Long-term mortality in hospitalized acute exacerbation of COPD patients with community-acquired pneumonia—a retrospective analysis. International Journal of Chronic Obstructive Pulmonary Disease. 2021:3551-9.
Yang J, Yang J. Association between blood eosinophils and mortality in critically ill patients with acute exacerbation of chronic obstructive pulmonary disease: a Retrospective Cohort Study. International Journal of Chronic Obstructive Pulmonary Disease. 2021:281-8.
Håkansson KE, Ulrik CS, Godtfredsen NS, Kallemose T, Andersen O, Eugen-Olsen J, et al. High suPAR and low blood eosinophil count are risk factors for hospital readmission and mortality in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease. 2020:733-43.
Steer J, Gibson J, Bourke SC. The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax. 2012;67(11):970-6.
Zhang Y, Liang L-R, Zhang S, Lu Y, Chen Y-Y, Shi H-Z, et al. Blood eosinophilia and its stability in hospitalized COPD exacerbations are associated with lower risk of all-cause mortality. International Journal of Chronic Obstructive Pulmonary Disease. 2020:1123-34.
Martínez-Gestoso S, García-Sanz M-T, Calvo-Álvarez U, Doval-Oubiña L, Camba-Matos S, Salgado F-J, et al. Variability of blood eosinophil count and prognosis of COPD exacerbations. Annals of Medicine. 2021;53(1):1153-9.
Yu S, Zhang J, Fang Q, Tong Z. Blood eosinophil levels and prognosis of hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease. The American Journal of the Medical Sciences. 2021;362(1):56-62.
Bafadhel M, Greening NJ, Harvey-Dunstan TC, Williams JE, Morgan MD, Brightling CE, et al. Blood eosinophils and outcomes in severe hospitalized exacerbations of COPD. Chest. 2016;150(2):320-8.
Abidi K, Khoudri I, Belayachi J, Madani N, Zekraoui A, Zeggwagh AA, et al. Eosinopenia is a reliable marker of sepsis on admission to medical intensive care units. Critical care. 2008;12:1-10.
Shaaban H, Daniel S, Sison R, Slim J, Perez G. Eosinopenia: Is it a good marker of sepsis in comparison to procalcitonin and C-reactive protein levels for patients admitted to a critical care unit in an urban hospital? Journal of critical care. 2010;25(4):570-5.
Wu H-X, Zhuo K-Q, Cheng D-Y. Peripheral blood eosinophil as a biomarker in outcomes of acute exacerbation of chronic obstructive pulmonary disease. International journal of chronic obstructive pulmonary disease. 2019:3003-15.
Ko FW, Chan KP, Ngai J, Ng SS, Yip WH, Ip A, et al. Blood eosinophil count as a predictor of hospital length of stay in COPD exacerbations. Respirology. 2020;25(3):259-66.
Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. The lancet Respiratory medicine. 2015;3(6):435-42.
Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. New England Journal of Medicine. 2018;378(18):1671-80.
Turato G, Semenzato U, Bazzan E, Biondini D, Tinè M, Torrecilla N, et al. Blood eosinophilia neither reflects tissue eosinophils nor worsens clinical outcomes in chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine. 2018;197(9):1216-9.
Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. European Respiratory Journal. 2014;44(6):1697-700.
Pavord ID, Lettis S, Locantore N, Pascoe S, Jones PW, Wedzicha JA, et al. Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD. Thorax. 2016;71(2):118-25.